Literature DB >> 8692500

Perinatal outcome in growth-restricted fetuses: do hypertensive and normotensive pregnancies differ?

J M Piper1, O Langer, E M Xenakis, M McFarland, B D Elliott, M D Berkus.   

Abstract

OBJECTIVE: To test the hypothesis that fetal growth restriction (FGR) associated with a maternal hypertensive disorder results in worse perinatal outcome than FGR in pregnancies without maternal hypertension.
METHODS: All consecutive, singleton, nondiabetic, small for gestational age (SGA) deliveries (birth weight at or below the tenth percentile for gestational age) in a 15-year computerized data base were analyzed for pregnancy outcome. Perinatal outcome was compared after stratification by presence or absence of hypertensive disorders and by gestational age at delivery.
RESULTS: Eleven thousand two hundred twenty-seven SGA pregnancies were analyzed. The morbidity and mortality profiles differed between hypertensive and normotensive pregnancies delivered preterm and those delivered at term. Perinatal mortality was significantly higher in the normotensive than in the hypertensive group in preterm deliveries (30.3 versus 18.7%, odds ratio [OR] 1.9 [confidence interval (CI) 1.3-2.9]). At term, hypertensive pregnancies demonstrated significantly higher mortality than normotensive pregnancies (4.6 versus 1.9%, OR 2.42 [95% CI 1.7-3.4]). In both preterm and term gestations, cesarean rates were significantly higher in hypertensive pregnancies than in normotensive pregnancies. Using logistic regression analysis, hypertension was independently associated with a 39% reduction in risk of perinatal mortality preterm, compared with a twofold increased risk of perinatal mortality at term.
CONCLUSION: Before term, FGR in normotensive women resulted in significantly higher perinatal mortality than FGR in hypertensive women. In contrast, at term, FGR in pregnancies complicated by hypertension had poorer perinatal outcomes than FGR in normotensive women.

Entities:  

Mesh:

Year:  1996        PMID: 8692500     DOI: 10.1016/0029-7844(96)02169-2

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  7 in total

Review 1.  Pathophysiology and maternal biologic markers of preeclampsia.

Authors:  Jacques Massé; Yves Giguère; Abdelaziz Kharfi; Joël Girouard; Jean-Claude Forest
Journal:  Endocrine       Date:  2002-10       Impact factor: 3.633

2.  Three alternative methods to resolve paradoxical associations of exposures before term.

Authors:  Nathalie Auger; Ashley I Naimi; William D Fraser; Jessica Healy-Profitós; Zhong-Cheng Luo; Anne Monique Nuyt; Jay S Kaufman
Journal:  Eur J Epidemiol       Date:  2016-06-20       Impact factor: 8.082

3.  Conventional birth weight standards obscure fetal growth restriction in preterm infants.

Authors:  Richard W I Cooke
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2006-03-17       Impact factor: 5.747

4.  Association of Maternal Preeclampsia With Infant Risk of Premature Birth and Retinopathy of Prematurity.

Authors:  Julia P Shulman; Cindy Weng; Jacob Wilkes; Tom Greene; M Elizabeth Hartnett
Journal:  JAMA Ophthalmol       Date:  2017-09-01       Impact factor: 7.389

5.  Risk of fetal death with preeclampsia.

Authors:  Quaker E Harmon; Lisu Huang; David M Umbach; Kari Klungsøyr; Stephanie M Engel; Per Magnus; Rolv Skjærven; Jun Zhang; Allen J Wilcox
Journal:  Obstet Gynecol       Date:  2015-03       Impact factor: 7.623

6.  Parenteral nutrition associated cholestasis is earlier, more prolonged and severe in small for gestational age compared with appropriate for gestational age very low birth weight infants.

Authors:  Soon Min Lee; Ran Namgung; Min Soo Park; Ho Sun Eun; Nam Hyo Kim; Kook In Park; Chul Lee
Journal:  Yonsei Med J       Date:  2013-07       Impact factor: 2.759

7.  Does advanced maternal age confer a survival advantage to infants born at early gestation?

Authors:  Sarka Lisonkova; Emmanuelle Paré; K S Joseph
Journal:  BMC Pregnancy Childbirth       Date:  2013-04-08       Impact factor: 3.007

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.